


#1113
Dmt
7-16-01
RECEIVED


JUL 13 2001

TECH CENTER 1600/2900

I hereby certify that this correspondence is being deposited with the United States Postal Service on the date set forth below as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

Date of Signature and Deposit: July 2, 2001


Nicholas J. Scay



PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ronald T. Raines

Date: _____, 2001

Serial No.: 09/234,028

Group Art Unit: 1652

Filed: 01/20/99

Examiner: R. Hutson

Title: OXIDATION-RESISTANT
RIBONUCLEASE INHIBITOR

File No.: 960296.95360

AMENDMENT

Commissioner For Patents
Washington DC 20231

RECEIVED
JUL 12 2001
TC 1700


Dear Sir:

In response to an Office Action dated January 2, 2001 in the file of the above-identified application, please amend the application as follows:

In the Specification:

Please insert the following new paragraph for the paragraph which previously appeared in the specification starting on page 5, line 31 and extending onto page 6, line 7.

RECEIVED
JUL 12 2001
TC 1700 MAIL ROOM

B1

An illustration of the three dimensional structure of the human ribonuclease inhibitor is illustrated in Fig. 1. The sequence of the ribonuclease inhibitor can be found in Lee et al. Biochemistry 27:8545-8553 (1988), the disclosure of which is hereby incorporated by reference. From both Figure 1 and the sequence of the protein, it can be readily seen that some of the cysteine residues are located adjacent to each other. The amino acid residues at

QBMAD\308226.1